Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | NAAA | Q02083 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 6/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1840884 | 1.00 | EPHX1 (0.61) | EPHX1NAAAACHETSHRFAAH | |
| SCHEMBL1836769 | 1.00 | EPHX1 (0.61) | EPHX1NAAAACHETSHRFAAH | |
| SCHEMBL1837803 | 1.00 | EPHX1 (0.61) | EPHX1NAAAACHETSHRFAAH | |
| SCHEMBL1840170 | 1.00 | EPHX1 (0.61) | EPHX1NAAAACHETSHRFAAH | |
| SCHEMBL1833843 | 1.00 | EPHX1 (0.61) | EPHX1NAAAACHETSHRFAAH | |
| SCHEMBL1833746 | 1.00 | EPHX1 (0.61) | EPHX1NAAAACHETSHRFAAH | |
| SCHEMBL1839720 | 1.00 | EPHX1 (0.61) | EPHX1NAAAACHETSHRFAAH | |
| SCHEMBL1837221 | 1.00 | EPHX1 (0.61) | EPHX1NAAAACHETSHRFAAH | |
| SCHEMBL1835070 | 1.00 | EPHX1 (0.61) | EPHX1NAAAACHETSHRFAAH | |
| SCHEMBL1835358 | 1.00 | EPHX1 (0.61) | EPHX1NAAAACHETSHRFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112724088-A | Uracil compound and anti-tumor application thereof | 中国医学科学院医药生物技术研究所 | 2021-04-30 | — | — | CN | claimed |
| CN-112618550-A | Antineoplastic uracil compound and lipid composition thereof | 中国医学科学院医药生物技术研究所 | 2021-04-09 | — | — | CN | claimed |
| US-20080161394-A1 | Cosmetic composition comprising at least one volatile carbonic acid ester | L'OREAL S.A. (FR) | 2008-07-03 | — | — | US | claimed |
| CN-122055369-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260085218-A1 | SEALANT RESIN COMPOSITION, AND USE THEREOF | MITSUI CHEMICALS, INC. (JP) | 2026-03-26 | — | — | US | disclosed |
| EP-4585663-A1 | SEALANT RESIN COMPOSITION AND USE OF SAME | Mitsui Chemicals, Inc. (JP) | 2025-07-16 | — | — | EP | disclosed |
| EP-3306732-B1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR BATTERIES AND LITHIUM SECONDARY BATTERY | MITSUI CHEMICALS INC (JP) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025125113-A1 | METHOD FOR PRODUCING A POROUS COMPOSITE ELECTRODE | VITO NV (BE) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025125114-A1 | METHOD FOR PREPARING HIGH-PERFORMANCE METAL POROUS ELECTRODES | VITO NV (BE) | 2025-06-19 | — | — | WO | disclosed |
| EP-4570952-A1 | METHOD FOR PREPARING HIGH-PERFORMANCE METAL POROUS ELECTRODES | Vito NV (BE) | 2025-06-18 | — | — | EP | disclosed |
| EP-4570951-A1 | METHOD FOR PRODUCING A POROUS ELECTRODE | Vito NV (BE) | 2025-06-18 | — | — | EP | disclosed |
| US-4891049-A | SUPPRESSION OF PARTICULATE EMISSION | UNION OIL COMPANY OF CALIFORNIA (US) | 1990-01-02 | — | — | US | disclosed |
| EP-0337640-A1 | Process for producing substituted vinyl pyridines | Takeda Chemical Industries, Ltd. (JP) | 1989-10-18 | — | — | EP | disclosed |
| US-4808620-A | ANTIINFLAMMATORY, ANALGESICS, ANTIPYRETIC, ANTIALLERGENS, ANTIARTHRITIC, ANTIRHEUMATIC AGENTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-02-28 | — | — | US | disclosed |
| EP-0135316-B1 | VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR PRODUCTION | Takeda Chemical Industries, Ltd. (JP) | 1988-07-13 | — | — | EP | disclosed |
| EP-0254241-A1 | Pyrazolopyridine compounds, their preparation and use | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1988-01-27 | — | — | EP | disclosed |
| US-4563446-A | ANTICOAGULANT, ANTISCHEMIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-01-07 | — | — | US | disclosed |
| EP-0135316-A1 | Vinyl carboxylic acid derivatives and their production | Takeda Chemical Industries, Ltd. (JP) | 1985-03-27 | — | — | EP | disclosed |
| US-4447365-A | ORGANOLEPTIC AGENT | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1984-05-08 | — | — | US | disclosed |
| US-4390463-A | Process for augmenting or enhancing the aroma of perfume compositions and colognes utilizing alkyl, aralkyl, and bicycloalkyl methyl carbonates | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1983-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085218-A1 | SEALANT RESIN COMPOSITION, AND USE THEREOF | RAD51, RPL24, F10 | EPHX1 1430/4885NAAA 2541/4885ACHE 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.